The management of infertility associated with polycystic ovary syndrome by Homburg, Roy
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Reproductive Biology and 
Endocrinology
Open Access Review
The management of infertility associated with polycystic ovary 
syndrome
Roy Homburg*
Address: Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Vrije Universiteit Medisch Centrum, Amsterdam, The 
Netherlands
Email: Roy Homburg* - r.homburg@vumc.nl
* Corresponding author    
Abstract
Polycystic ovary syndrome [PCOS] is the commonest cause of anovulatory infertility. Treatment
modes available are numerous mainly relying on ovarian stimulation with FSH, a reduction in insulin
concentrations and a decrease in LH levels as the basis of the therapeutic principles. Clomiphene
citrate is still the first line treatment and if unsuccessful is usually followed by direct FSH
stimulation. This should be given in a low dose protocol, essential to avoid the otherwise prevalent
complications of ovarian hyperstimulation syndrome and multiple pregnancies. The addition of a
GnRH agonists, while very useful during IVF/ET, adds little to ovulation induction success whereas
the position of GnRH antagonists is not yet clear. Hyperinsulinemia is the commonest contributor
to the state of anovulation and its reduction, by weight loss or insulin sensitizing agents such as
metformin, will alone often restore ovulation or will improve results when used in combination
with other agents. Laparoscopic ovarian drilling is proving equally as successful as FSH for the
induction of ovulation, particularly in thin patients with high LH concentrations. Aromatase
inhibitors are presently being examined and may replace clomiphene in the future. When all else
has failed, IVF/ET produces excellent results. In conclusion, there are very few women suffering
from anovulatory infertility associated with PCOS who cannot be successfully treated today.
Review
Polycystic ovary syndrome [PCOS] is associated with
approximately 75% of women who suffer from infertility
due to anovulation [1,2]. It is a very heterogeneous syn-
drome both in its clinical presentation and laboratory
manifestations. The majority of women with anovulation
due to PCOS have menstrual irregularities, usually oli-
gomenorrhea or amenorrhea, associated with clinical
and/or biochemical evidence of hyperandrogenism. The
main disturbances in this syndrome are:
1. Abnormal morphology of the ovary, detected by a char-
acteristic hyperechogenic enlarged central stroma and >9
small follicles of 2–9 mm diameter on transvaginal ultra-
sound examination of the ovaries [3].
2. Abnormal steroidogenesis, mainly increased ovarian
production of androgens but also increased progesterone
and estradiol production.
3. Hyperinsulinemia, present in about 80% of obese
women and 30–40% of women of normal weight with
PCOS [4] and more strongly associated with anovulation
than any other feature of the syndrome.
Published: 14 November 2003
Reproductive Biology and Endocrinology 2003, 1:109
Received: 21 March 2003
Accepted: 14 November 2003
This article is available from: http://www.rbej.com/content/1/1/109
© 2003 Homburg; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/109
Page 2 of 9
(page number not for citation purposes)
4. Abnormal gonadotrophin secretion, most commonly
manifested as increased serum LH concentrations in 40%
of women with ultrasonically detected PCO [5]. A func-
tional deficiency of the endogenous action of FSH also
seems to be present in women with anovulatory PCOS.
Several modes of inducing ovulation for these patients
will now be described. It will be seen that they basically
depend on either a reduction of insulin concentrations,
FSH stimulation or a reduction of LH concentrations or a
combination of these.
Weight loss
Excess body weight is a common problem of modern soci-
ety, reaching epidemic proportions in some countries. For
women with PCOS, an excess of body fat accentuates insu-
lin resistance and its associated clinical sequelae. Central
obesity and BMI are major determinants of insulin resist-
ance, hyperinsulinemia and hyperandrogenemia. The rate
of insulin resistance in women with PCOS is 50–80% and
a large majority of these women are obese [6,7].
They almost inevitably have the stigmata of hyperandro-
genism and irregular or absent ovulation. Insulin stimu-
lates LH and ovarian androgen secretion and decreases sex
hormone binding globulin concentrations [8].
The successful treatment of obesity and hyperinsulinemia
is capable of reversing their deleterious effects, of which
there are several, on the outcome of treatment. More
gonadotrophins are required to achieve ovulation in insu-
lin resistant women [9,10]. Obese women being treated
with low dose gonadotrophin therapy have inferior preg-
nancy and miscarriage rates [11]. Both obese [12] and
insulin resistant [10] women with PCOS, even on low
dose FSH stimulation, have a much greater tendency to a
multifollicular response and thus a relatively high cycle
cancellation rate in order to avoid hyperstimulation.
Just as obesity expresses and exaggerates the signs and
symptoms of insulin resistance, then loss of weight can
reverse this process by improving ovarian function and
the associated hormonal abnormalities [13–15]. Loss of
weight induces a reduction of insulin and androgen con-
centrations and an increase in sex hormone binding hor-
mone concentrations. Curiously, in obese women with
PCOS, a loss of just 5–10% of body weight is enough to
restore reproductive function in 55–100% within 6
months of weight reduction [13–15]. Weight loss has the
undoubted advantages of being effective and cheap with
no side effects and should be the first line of treatment in
obese women with anovulatory infertility associated with
PCOS.
Clomiphene citrate
The introduction of even small amounts of FSH into the
circulation either directly with FSH injections or indirectly
with with pulsatile GnRH or clomiphene citrate, is capa-
ble of inducing ovulation and pregnancy in a large
number of anovulatory women with PCOS. Clomiphene
citrate has long been the first line of treatment for those
with absent or irregular ovulation. It is given in a dose of
50–250 mg per day for 5 days starting from day 2–5 of
spontaneous or induced bleeding starting with the lowest
dose and raising the dose in increments of 50 mg/day
each cycle until an ovulatory cycle is achieved. In practice,
I almost inevitably use a starting dose of 100 mg per day
from day 4 or 5 and have found no advantage in using a
daily dose of more than 150 mg which seems neither to
significantly increase the ovulation rate nor follicular
recruitment. This sort of regimen will cut down the
number of 'superfluous' cycles of treatment until ovula-
tion is achieved and until those resistant to clomiphene
are identified. A course of 3–6 ovulatory cycles is usually
sufficient to know whether pregnancy will be achieved
using clomiphene citrate before moving on to more com-
plex treatment as approximately 75% of the pregnancies
achieved with clomiphene occur within the first three
cycles of treatment [16].
Ovulation is restored in approximately 80% but will
result in pregnancy in only about 35–40% of patients who
are given clomiphene [16–18]. Additionally, around 20–
25% of anovulatory women with PCOS will not respond
at all to clomiphene citrate and are considered to be 'clo-
miphene resistant' [19,20]. Patients who do not respond
to clomiphene are likely to be more obese, insulin resist-
ant and hyperandrogenic than those who do respond
[20]. As clomiphene citrate induces a discharge of LH as
well as FSH and elevated LH concentrations are believed
to impede conception, those with high basal LH levels are
also less likely to respond to clomiphene treatment [21].
The most probable factor involved in this large discrep-
ancy between ovulation and pregnancy rates in patients
treated with clomiphene is the anti-estrogenic effects of
clomiphene at the level of the endometrium and cervical
mucus. While the depression of the cervical mucus, occur-
ring in about 15% of patients, may be overcome by per-
forming intra-uterine insemination [IUI], suppression of
endometrial proliferation, unrelated to dose or duration
of treatment but apparently idiosyncratic, indicates a poor
prognosis for conception in my experience when endome-
trial thickness never reaches 8 mm. Monitoring of the clo-
miphene treated cycle by ultrasound evaluation of
follicular growth, endometrial thickness and even estra-
diol and progesterone concentrations on day 12–14 of the
cycle is justified by the identification of those who are not
responding or have depressed endometrial thickness and
is helpful in the timing of natural intercourse or IUI.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/109
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Although this monitoring implies added expense, this is
neutralized by the prevention of protracted periods of
possibly inappropriate therapy and delay in the inception
of more efficient treatment.
The results of clomiphene treatment may be improved by
co-treatment with several proposed adjuvants. The addi-
tion of an ovulatory dose of hCG, 5,000–10,000 IU is
only theoretically warranted when the reason for a non-
ovulatory response is that the LH surge is delayed or
absent despite the presence of a well developed follicle.
Although the routine addition of hCG at mid-cycle seems
to add little to the improvement of conception rates [22].
I have found it very useful, given when an ultrasonically
demonstrated leading follicle attains a diameter of 18–24
mm, for the timing of intercourse or IUI.
Daily doses of dexamethasone, 0.5 mg at bedtime, as an
adjunct to clomiphene therapy, suppress the adrenal
androgen secretion and may induce responsiveness to clo-
miphene in previous non-responders, mostly hyperan-
drogenic women with PCOS with elevated concentrations
of dehydroepiandrosterone sulphate [DHEAS] [23,24].
Although this method meets with some success, medium
to long term glucocorticoid steroid therapy often induces
side effects including increased appetite and weight gain
which is not an appealing proposition for women with
PCOS.
The combined treatment of clomiphene with metformin
is dealt with in the section on metformin.
Aromatase inhibitors
Aromatase inhibitors have been suggested as an alterna-
tive treatment to clomiphene as the discrepancy between
ovulation and pregnancy rates with clomiphene citrate
has been attributed to its anti-estrogenic action and estro-
gen receptor depletion. The aromatase inhibitors do not
possess the adverse anti-estrogenic effects of clomiphene
but, by suppressing estrogen production, mimic the cen-
tral reduction of negative feedback through which clomi-
phene works. Letrozole, the most prevalently used anti-
aromatase for this indication, has been shown to be effec-
tive, in early trials, in inducing ovulation and pregnancy
in women with anovulatory PCOS and inadequate clomi-
phene response [25] and improving ovarian response to
FSH in poor responders [26]. Evidence from larger trials is
still awaited but some encouragement may be taken from
the solidity of the working hypothesis and the success of
the preliminary results.
Gonadotrophin therapy
Gonadotrophin [FSH] therapy is usually the next step fol-
lowing failure with clomiphene, i.e. there has been no
response to clomiphene in a daily dose of 150 mg or 4–6
ovulatory cycles have not resulted in a pregnancy.
The main complications of gonadotrophin therapy, ovar-
ian hyperstimulation syndrome [OHSS] and multiple
pregnancies, are both caused by multiple follicular devel-
opment. Anovulatory women with PCOS are particularly
prone to multiple follicular development when receiving
gonadotrophins.
Acceptable cumulative conception rates have been
achieved using conventional step-up treatment with gona-
dotrophins for women with PCOS. However, because of
the peculiarly high sensitivity of polycystic ovaries to
gonadotrophin stimulation, this form of treatment,
employing incremental dose rises of 75 IU every 5–7 days,
characteristically induces multiple follicular develop-
ment, resulting in a high frequency of multiple pregnan-
cies and ovarian hyperstimulation syndrome [OHSS]. A
review by Hamilton-Fairley & Franks [27] reported a
mean multiple pregnancy rate of 34% and severe OHSS of
4.6%. In a further study, although this traditional proto-
col produced a cumulative conception rate of 82% after
six cycles, it was plagued by an unacceptable rate of mul-
tiple pregnancies and OHSS [28]. The supraphysiological
doses of FSH used in the conventional protocol provoke
an initial development of a large cohort, stimulate addi-
tional follicles, and even rescue those follicles destined for
atresia [29]. Levels of FSH well above the threshold induce
a multiple follicular development. While this can be uti-
lized for the induction of superovulation for in-vitro ferti-
lization and embryo transfer, for the induction of
ovulation in women with PCOS the problem of achieving
the desired monofollicular ovulation is particularly diffi-
cult and acute due to the extreme sensitivity of the poly-
cystic ovary to gonadotrophic stimulation. This is not due
to a difference of FSH threshold levels of the polycystic
ovaries but probably to the fact that they contain twice the
number of available FSH-sensitive antral follicles in their
cohort compared with the normal ovary [30]. Any dose of
FSH overstepping the threshold of the polycystic ovary
will, therefore, produce multifollicular development and
impending danger of multiple pregnancy and OHSS.
The chronic low dose regimen of FSH was designed to
reduce the rate of complications due to multiple follicular
development [For review, see ref. [31], the reasoning
being that the 'threshold theory', demanding the attain-
ment and maintenance of follicular development with
exogenous FSH without exceeding the threshold require-
ment of the ovary should be employed. The principle of
the classic chronic low dose regimen is to employ a low
starting dose for 14 days and then use small incremental
dose rises when necessary, at intervals of not less than 7
days, until follicular development is initiated [32,33]. TheReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/109
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dose that initiates follicular development is continued
until the criteria for giving hCG are attained. This form of
therapy aims to achieve the development of a single dom-
inant follicle rather than the development of many large
follicles and thereby avoid the complications of OHSS
and multiple pregnancies.
A comparative prospective study of the conventional regi-
men with chronic low dose administration of FSH for
anovulation associated with PCOS [28] involved 50 par-
ticipants treated with FSH, half of them using a conven-
tional stepwise protocol [incremental dose rises of 75 IU
every 5–7 days when necessary] and half with a regimen
of chronic low dose as described above. Both methods of
treatment had an initial dose of 75 IU FSH. Compared
with the conventional dose protocol, the chronic low dose
regimen yielded slightly improved pregnancy rates [40%
versus 24%] while completely avoiding OHSS and multi-
ple pregnancies, which were prevalent [11% OHSS and
33% multiple pregnancies] with conventional therapy.
Uniovulation was induced in 74% versus 27% of cycles
and the total number of follicles > 16 mm and estradiol
concentrations were half those observed on conventional
therapy. A large French multicentre study [34] with an
identical objective and protocol design compared conven-
tional and chronic low dose regimens in 103 anovulatory
WHO Group II women. The comparison of low with con-
ventional dose revealed pregnancy rates of 33.3% versus
20%, and with a multiple [twins] pregnancy rate of 14%
and 22%, respectively. The total number of follicles > 10
mm and estradiol concentrations on the day of hCG in the
low dose group were half those seen on conventional
therapy. Additionally, the low dose regimen tended to
produce a higher rate of mono- or bifollicular develop-
ment in this study.
Reported results [31] using a chronic low dose protocol
identical to that described above, show a remarkably con-
sistent rate of uniovulatory cycles of around 70% and an
acceptable pregnancy rate of 40% of the patients and 20%
per cycle. However, the justification for the adoption of
the chronic low dose protocol may be seen in the almost
complete elimination of OHSS and a multiple pregnancy
rate of <6%.
In the normal ovulatory cycle, decreasing FSH concentra-
tions are seen throughout the follicular phase. In order to
mimic more closely the events of the normal ovulatory
cycle, the Rotterdam group examined a step-down dose
regimen with a starting dose of 150 IU and decreasing the
dose by 0.5 ampoules when a follicle of 10 mm ensues
and by the same amount every 3 days if follicular growth
continues [35,36]. A comparison of this regimen with the
classic step-up regimen from the same group [37] demon-
strated a monofollicular growth rate of 88% of cycles in
the step-down regimen compared with 56% with the step-
up protocol. In the step-down group, duration of treat-
ment and gonadotrophin requirement were significantly
reduced. However, a recently concluded randomized,
French multicenter study comparing the step-up versus
the step-down protocol demonstrated superiority of the
step-up regimen as regards the rates of monofollicular
development, overstimulation and ovulation. [38]
Assuming that the step-up protocol is superior to the step-
down version, do the initial dose, the duration of its
administration and the incremental dose rise influence
results? From the largest published series of chronic low
dose FSH therapy [12] it was possible to compare the
results of a starting dose of 75 IU with that of 52.5 IU for
an initial 14-day period with an incremental dose rise of
37.5 IU or 22.5 IU respectively. There were no significant
differences between the two groups but pregnancy rate/
patient, uni-ovulatory cycle rate and miscarriage rate were
all in favour of the smaller starting dose.
Although the majority of patients with PCOS will reach
criteria for hCG administration within 14 days using 75
IU/day of urinary FSH [12] or 50 IU/day of recombinant
FSH, some have attempted to cut down the initial period
of 14 days without change of dose to 7 days. A compari-
son of 14 day versus 7 day starters [31] in 50 patients
showed no significant differences other than a slightly
higher rate of multiple pregnancies in the 7-day group. As
we regarded a multiple pregnancy as a 'failure' of treat-
ment, we reverted back to the 14 day initial period with-
out any change of dose.
A recently completed multicenter study employing a step-
up protocol starting with doses of 50 IU/day of 'Puregon'
for a minimum of 7 days, compared two randomized
groups using incremental dose rises of 25 IU or 50 IU
when needed [H.J. Out, personal communication]. The
use of the smaller incremental dose rises was significantly
more beneficial in terms of monofollicular development,
ovulation rates and cancellation rates.
To summarise, low dose, step-up gonadotrophin therapy
should be preferred to the now outdated conventional
therapy for patients with PCOS. Small starting doses in
the first cycle for a 14-day initial period without a dose
change and then a small incremental dose rise if required,
seem on present evidence to give the best results.
GnRH agonists
The ability of GnRH agonists to suppress LH concentra-
tions before and during ovarian stimulation has earned
them an undisputed place in IVF treatment protocols.
They confer the advantage of eliminating, almost com-
pletely, the annoying occurrence of premature luteiniza-Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/109
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tion. In addition, some investigators have reported more
pregnancies, possibly better quality eggs and less miscar-
riages [39]. Their possible application during ovulation
induction should therefore be particularly relevant in the
presence of the chronic, tonic, high serum concentrations
of LH observed in a high proportion of women with
PCOS. Theoretically, by suppressing LH concentrations,
GnRH agonists should eliminate premature luteinization
and alleviate the relatively low pregnancy rates and the
high miscarriage rates witnessed in this group of patients
[9]. In a large study [40] 239 women with PCOS received
hMG with or without GnRH agonist for ovulation induc-
tion or superovulation for IVF/embryo transfer. Of preg-
nancies achieved with GnRH agonist, 17.6% miscarried
compared with 39% of those achieved with gonado-
trophins alone. Cumulative live birth rates after four
cycles for GnRH agonist were 64% compared with 26%
for gonadotrophins only.
The GnRH agonist has not become standard treatment for
ovulation induction in PCOS despite the fact that our
experience and that of others has shown an increased
pregnancy rate and lower miscarriage rate in women
receiving combination treatment of agonist and gonado-
trophins when tonic LH concentrations are high [42].
There are several reasons for this apparent anachronism.
Co-treatment with GnRH agonist and low dose gonado-
trophin therapy is more cumbersome, longer, requires
more gonadotrophins to achieve ovulation, has a greater
prevalence of multiple follicle development and conse-
quently more OHSS and multiple pregnancies. This com-
bination therapy should be reserved for women with high
serum concentrations of LH who have repeated premature
luteinization, stubbornly do not conceive on gonado-
trophin therapy alone or who have conceived and had
early miscarriages on more than one occasion.
There is no doubt that GnRH agonists cannot help to
reduce the incidence of OHSS and multiple pregnancies
in PCOS ovulation induction. If anything, combining
GnRH agonist with gonadotrophin stimulation will exac-
erbate the problem of multiple follicular development
and therefore increase rates of cycle cancellation, OHSS
and multiple pregnancy [41,42]. This may be due to sev-
eral factors: loss of the endogenous feedback mechanism
when using GnRH agonist, reduction of intra-follicular
androgen levels following pituitary down regulation and
consequently postponed atresia and, most probably,
greater stimulation of follicles by the larger amounts of
gonadotrophins needed when using GnRH agonist. A
GnRH agonist is not the solution to the problem of mul-
tiple follicular development.
The two main complications of ovulation induction for
PCOS are multifollicular development and the possible
deleterious effects of high LH levels, low conception rates
and high miscarriage rates. A combination of chronic low
dose FSH stimulation with GnRH agonist therapy should
theoretically therefore yield the best results. Scheele et al.
[43] studied women with PCOS undergoing ovulation
induction with chronic low dose FSH therapy, one group
with and one without adjuvant GnRH agonist therapy. A
very low rate of monofollicular ovulation was achieved
[14%] in the agonist cycles compared with 44% of those
treated with low dose FSH alone. Treatment with GnRH
agonist abolished neither the inter- nor intra-individual
variability of the FSH dose required to induce ongoing fol-
licular growth but also seemed to induce an even further
increase in the sensitivity of the PCO follicles to gonado-
trophin stimulation once the threshold FSH dose had
been reached.
GnRH antagonists
The antagonists have some advantages over the agonists
and these may well become utilized in the treatment of
anovulatory PCOS. Firstly, antagonists act by the mecha-
nism of competitive binding and this allows a modula-
tion of the degree of hormonal suppression by adjustment
of the dose. Further, antagonists suppress gonadotrophin
release within a few hours, have no flare-up effect and
gonadal function resumes without a lag effect following
their discontinuation. If we apply these advantages to an
ovulation induction protocol for PCOS, one can visualize
that, used in combination with low dose FSH administra-
tion, the antagonist could be given in single or repeated
doses when a leading follicle of 13–14 mm is produced.
This would theoretically prevent premature luteinization,
protect the oocyte from deleterious effects of high LH con-
centrations and still allow the follicle to grow unhindered
to ovulatory size. Compared to agonist treated cycles this
would confer the, again, theoretical advantages of a much
shorter cycle of treatment, promise more conceptions and
less miscarriages, reduce the amount of gonadotrophin
required and increase the incidence of monofollicular
ovulation with a consequent reduction in the prevalence
of OHSS and multiple pregnancies. Only one trial
employing a GnRH antagonist with recombinant FSH,
specifically for women with PCOS, has been published to
date [44]. Following pre-treatment with oral contracep-
tives, a GnRH antagonist was started on in 20 patients on
day 2 of the cycle. When LH concentrations were found to
be suppressed, concurrent antagonist and recombinant
FSH therapy was started and continued until the day of
hCG. LH was effectively suppressed by one dose of antag-
onist and all patients ovulated. Overall clinical pregnancy
rates were 44% and on-going pregnancy rates 28%. This is
a preliminary trial but large RCT's are needed to confirm
these results.Reproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/109
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Metformin
The basic etiology behind the anovulation associated with
PCOS is mainly insulin resistance and hyperinsulinemia
[45,46]. This strong association between hyperinsuline-
mia and anovulation would suggest that a reduction of
insulin concentrations could be of great importance.
Weight loss for the obese can reverse this situation as
mentioned above but for those who fail to lose weight or
are of normal weight but hyperinsulinaemic, an insulin
sensitizing agent such as metformin is indicated. How-
ever, the indications for the administration of metformin
to anovulatory women with PCOS in an ovulation induc-
tion program have widened as it seems to be difficult to
predict which individuals will respond well with this
medication [46]. Metformin is an oral biguanide, well
established for the treatment of hyperglycaemia, that does
not cause hypoglycaemia in normoglycaemic patients.
The sum total of its actions is a decrease in insulin levels
and, as a consequence, a lowering of circulating total and
free androgen levels with a resulting improvement of the
clinical sequelae of hyperandrogenism.
There are now a large number of studies published on the
effect of metformin in a dose of 1500–2550 mg/day in
women with PCOS. The vast majority of these studies
have demonstrated a significant improvement in insulin
concentrations, insulin sensitivity, and serum androgen
concentrations accompanied by decreased LH and
increased SHBG concentrations [48]. The restoration of
regular menstrual cycles by metformin has been reported
in the large majority of published series and the reinstate-
ment of ovulation occurred in 78%-96% of patients [45–
50]. Fleming et al [46], in the largest randomized control-
led trial published to date, demonstrated a significantly
increased frequency of ovulation with metformin as com-
pared to placebo in a group of 92 oligomenorrheic
women with PCOS. This was achieved without any signif-
icant changes in the insulin response to glucose challenge
after 14 weeks of metformin treatment in a dose of 850
mg, twice a day.
In a randomised controlled trial [RCT] performed on clo-
miphene resistant infertile patients with PCOS, compared
with placebo, metformin markedly improved ovulation
and pregnancy rates with clomiphene treatment [51]. In a
large study, 46 anovulatory obese women with PCOS who
did not ovulate on metformin or placebo for 35 days were
given 50 mg of clomiphene daily for 5 days while contin-
uing metformin or placebo. Of those on metformin, 19 of
21 ovulated compared with 2 of 25 on placebo [47].
When women with clomiphene resistant PCOS were
administered FSH with or without pretreatment with met-
formin for one month in an RCT, those receiving met-
formin developed significantly less large follicles,
produced less estradiol and had fewer cycles cancelled due
to excessive follicular development. The reduction of insu-
lin concentrations induced by metformin seemed to
favour a more orderly follicular growth in response to
exogenous gonadotrophins for ovulation induction [52].
In the one published study on the effects of metformin on
clomiphene resistant patients undergoing IVF/ICSI, the
results of cycles preceded by treatment with metformin
were compared retrospectively to those in which met-
formin was not given. Those receiving metformin had a
decreased total number of follicles but no difference in the
mean number of oocytes retrieved. There were more
mature oocytes, embryos cleaved, increased fertilisation
and clinical pregnancy rates [70% vs 30%] in the met-
formin group [53]. These latter two studies would seem to
confirm that both obese [12] and insulin resistant [10]
women with PCOS have a much greater tendency to a
multifollicular response and thus a relatively high cycle
cancellation rate on low dose FSH stimulation.
The evidence so far is encouraging concerning the effi-
ciency and safety of metformin as a single agent or in com-
bination with clomiphene citrate or gonadotrophins for
induction of ovulation in women with hyperinsulinaemic
PCOS [54]. It remains to be seen whether metformin,
which probably also has a direct androgen lowering
action on the ovary, will be of help to all women with
PCOS wishing to conceive. Not only does metformin
seem to be safe when continued throughout pregnancy
but preliminary data strongly suggest that this strategy can
severely decrease the high miscarriage rate usually associ-
ated with PCOS [55,56]. It is hoped that the apparent lack
of terratogenicity and beneficial effect of metformin on
miscarriage rates will be confirmed by future studies.
Other compounds with the property of lowering insulin
concentrations, the glitazones rosiglitazone and pioglita-
zone, and d-chiro-inositol, are under investigation and
may also prove useful for women with anovulatory PCOS.
Laparoscopic ovarian drilling
Laparoscopic ovarian drilling [LOD] by diathermy or laser
now presents a further treatment option for women with
anovulatory infertility associated with polycystic ovary
syndrome. This laparoscopic version of ovarian wedge
resection employs a unipolar coagulating current or punc-
ture of the ovarian surface with a laser in 4–10 places to a
depth of 4–10 mm on each ovary. An analysis [57] of the
first 35 reports, mostly uncontrolled series, showed that
82% of 947 patients ovulated following the operation and
63% conceived either spontaneously or after treatment
with medications to which they had previously been
resistant. A Cochrane data base analysis of six randomized
controlled trials [58] mostly comparing laparoscopic
ovarian drilling with gonadotrophin therapy, showedReproductive Biology and Endocrinology 2003, 1 http://www.rbej.com/content/1/1/109
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similar cumulative ongoing pregnancy rates 6–12 months
after LOD and after 3–6 cycles of gonadotrophin therapy
[58]. A large, recently completed, multicenter study in The
Netherlands, showed parity in the results of LOD and
low-dose FSH therapy [Bayram et al., submitted for publi-
cation]. The Cochrane analysis [58] highlighted the main
advantage of ovarian drilling – a very high prevalence of
monofollicular ovulation and therefore a significant
reduction in multiple pregnancy rates compared with
gonadotrophin therapy. Further possible advantages of
LOD are a reported reduction in miscarriage rates [59], the
fact that it is an often successful "one-off" procedure
which may avoid the use of expensive medical therapy
and the exclusion of ovarian hyperstimulation syndrome.
If ovulation is not forthcoming within 2–3 months fol-
lowing LOD, then ovulation induction can often be more
successfully employed than preceeding the operation.
However, in a large number of cases spontaneous ovula-
tion has been induced even for several years following
LOD in a similar fashion to ovarian wedge resection, the
"predecessor" of LOD [60]. As LOD is less invasive and
causes less pelvic adhesions then ovarian wedge resection,
there is every reason to expect similar or even more
impressive results from LOD than present evidence sug-
gests. Those who are slim and have high LH concentra-
tions seem to have the most favourable prognosis [61].
However, the mechanism involved in the restoration of
ovulation is quite unknown although the principle endo-
crine change is a dramatic decrease in LH concentrations
about two days after the operation.
IVF/ET
If all else fails for the infertile PCOS patient then in-vitro
fertilization is a last resort providing excellent results.
Although a smaller percentage of recovered oocytes are
fertilized, the larger number of oocytes recovered from
PCOS patients balances out the pregnancy rate in compar-
ison with, for example, women with a mechanical factor
[39]. In-vitro maturation of oocytes from women with
PCOS may become a possible option [62]. However, it is
proving technically difficult at present and concerns over
the well being of pregnancies achieved from IVM have not
yet been fully answered.
Conclusions
Following weight loss if warranted, clomiphene citrate is
the usual first-line treatment. If clomiphene fails to induce
ovulation and pregnancy, several therapeutic paths are
open depending on the individual case: low dose FSH
therapy, addition of metformin to clomiphene or FSH
treatment, laparoscopic ovarian drilling and finally, IVF.
Alternative possibilities for treatment in the near future
include aromatase inhibitors and in-vitro maturation of
oocytes. Whatever the treatment option used, there are
very few women today who suffer from pure anovulatory
infertility due to PCOS who will remain involuntarily
childless.
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